Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS884448 in advanced cancer
NCT04335253Phase 1Completed
- Sponsor
- iTeos Therapeutics
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belrestotug in cancer, sponsored by iTeos Therapeutics. Primary endpoints: Percentage of participants with Adverse Events up to 48 weeks, Percentage of participants who experience a Dose Limiting Toxicity at 28 days and 1 more. Started Feb 2020; status: completed.
02
Drugs
belrestotug
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04335253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335253.